AU2006342137B2 - Glucagon receptor antagonists, preparation and therapeutic uses - Google Patents

Glucagon receptor antagonists, preparation and therapeutic uses Download PDF

Info

Publication number
AU2006342137B2
AU2006342137B2 AU2006342137A AU2006342137A AU2006342137B2 AU 2006342137 B2 AU2006342137 B2 AU 2006342137B2 AU 2006342137 A AU2006342137 A AU 2006342137A AU 2006342137 A AU2006342137 A AU 2006342137A AU 2006342137 B2 AU2006342137 B2 AU 2006342137B2
Authority
AU
Australia
Prior art keywords
dimethyl
isomer
benzamide
tetrazol
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006342137A
Other languages
English (en)
Other versions
AU2006342137A1 (en
Inventor
Scott Eugene Conner
Philip Arthur Hipskind
Jianke Li
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2006342137A1 publication Critical patent/AU2006342137A1/en
Application granted granted Critical
Publication of AU2006342137B2 publication Critical patent/AU2006342137B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006342137A 2005-11-22 2006-11-16 Glucagon receptor antagonists, preparation and therapeutic uses Ceased AU2006342137B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73872305P 2005-11-22 2005-11-22
US60/738,723 2005-11-22
PCT/US2006/060976 WO2007120270A2 (en) 2005-11-22 2006-11-16 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (2)

Publication Number Publication Date
AU2006342137A1 AU2006342137A1 (en) 2007-10-25
AU2006342137B2 true AU2006342137B2 (en) 2012-02-16

Family

ID=38609982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006342137A Ceased AU2006342137B2 (en) 2005-11-22 2006-11-16 Glucagon receptor antagonists, preparation and therapeutic uses

Country Status (9)

Country Link
US (1) US8691856B2 (enExample)
EP (1) EP1957068B1 (enExample)
JP (1) JP5230436B2 (enExample)
CN (1) CN101312723B (enExample)
AU (1) AU2006342137B2 (enExample)
BR (1) BRPI0618140A2 (enExample)
CA (1) CA2629172C (enExample)
ES (1) ES2516691T3 (enExample)
WO (1) WO2007120270A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AU2011346670B2 (en) * 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CN108727157B (zh) * 2018-07-06 2020-04-28 大连理工大学 胰高血糖素受体拮抗剂中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973731A (en) 1987-04-23 1990-11-27 Riker Laboratories, Inc. Di-t-butylphenyl alkyl and benzyl ether nitriles
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
JP2006500325A (ja) * 2002-06-27 2006-01-05 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2004056763A2 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Novel glucagon antagonists
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CN101312723B (zh) 2012-01-11
AU2006342137A1 (en) 2007-10-25
JP2009516698A (ja) 2009-04-23
WO2007120270A2 (en) 2007-10-25
WO2007120270A3 (en) 2008-02-28
CN101312723A (zh) 2008-11-26
CA2629172C (en) 2014-05-06
US20090156655A1 (en) 2009-06-18
ES2516691T3 (es) 2014-10-31
EP1957068A2 (en) 2008-08-20
JP5230436B2 (ja) 2013-07-10
US8691856B2 (en) 2014-04-08
EP1957068B1 (en) 2014-08-13
CA2629172A1 (en) 2007-10-25
BRPI0618140A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
EP1957068B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
US7696248B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
AU2006342059B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951658B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629321C (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MX2008006699A (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired